首頁 > 市場調查報告書 > 材料/化學品

化學品界面活性劑

市場調查報告書

商品編碼

2008006

肺表面活性劑市場：按類型、藥物類型、適應症、給藥途徑、分銷管道和地區分類

Pulmonary Surfactant Market, By Type, By Drug Type, By Indications, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年03月27日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

肺表面活性劑市場預計在2026年達到7.232億美元，預計到2033年將達到9.478億美元。預計從2026年到2033年，其複合年成長率將達到7.2%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	7.232億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	7.20%	2033年市場規模預測：	9.478億美元

肺表面活性物質是由脂質和蛋白質組成的複雜物質，富含界面活性劑，存在於覆蓋肺泡表面的液體中。表面活性物質在肺的生理功能中發揮著至關重要的作用。其主要生物物理功能是防止肺容量不足時發生肺泡塌陷，並在正常呼吸和用力呼吸期間維持細支氣管通暢性。其主要非生物物理和免疫學功能是保護肺部免受吸入顆粒和微生物的損傷和感染。肺表面活性物質在生化組成、形態結構和特定生物物理功能方面具有異質性。界面活性物質可防止肺容量不足時發生肺泡塌陷。

此外，肺表面活性物質也發揮保護肺部免受吸入顆粒和微生物損傷和感染的作用（免疫和非生物物理功能）。肺表面活性物質只能透過肺部灌洗法收集，而這種方法可能會破壞現有的生物物理和生物化學微結構。在解讀肺表面活性物質的體外研究結果時，必須始終考慮這些限制。

市場動態

預計在預測期內，多種呼吸道感染疾病和呼吸系統疾病的日益普及將推動全球肺表面活性劑市場的發展。例如，截至2022年5月20日，全球報告的慢性阻塞性肺病（COPD）死亡病例中，90%發生在70歲以下的患者中，主要集中在印度、韓國和孟加拉等中低收入國家。慢性阻塞性肺病是全球主要死因之一，2019年造成323萬人死亡。

新療法核准數量的不斷增加是全球肺表面活性劑市場成長的主要驅動力之一。例如，2020年7月，製藥公司勃林格殷格翰宣布，歐盟委員會核准尼達尼布用於治療成人其他慢性纖維化間質性肺部疾病（ILD），這些疾病的表現型進行性超出特發性肺纖維化（IPF）。此前，人用藥品委員會（CHMP）於2020年5月核准了正面意見。美國食品藥物管理局（FDA）、加拿大衛生署和日本藥品和醫療設備管理局（PMDA）也已核准尼達尼布用於治療類似患者族群。此次核准是基於 INBUILD 試驗的結果，這是一項隨機、雙盲、安慰劑對照、平行組 III 期試驗，旨在評估尼達尼布治療進行進行性慢性纖維化間質性肺病 (ILD) 患者的療效、安全性和耐受性。

本次考試的主要特點。

本報告對全球肺表面活性劑市場進行了詳細分析，以 2021 年為基準年，給出了預測期（2022-2030 年）的市場規模。
本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新藥上市和核准、區域前景以及主要企業所採用的競爭策略的關鍵見解。
本報告根據以下參數對全球肺表面活性劑市場的主要企業進行了分析：公司概況、財務業績、產品系列、地理分佈、分銷策略、關鍵發展和策略以及未來計劃。
透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
本報告面向該產業的各類相關人員，包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
透過各種用於分析全球肺表面活性劑市場的策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第10章競爭格局

熱圖分析
公司簡介
- Boehringer Ingelheim
- AbbVie Inc.
- Chiesi Farmaceutici
- ONY Biotech Inc.
- Lyomark Pharma
- Abbott
- Aviva Systems Biology Corporation
- Windtree Therapeutics, Inc
- Tekzima（Noargen）
- Biomatik
- Nanjing Norris Pharm Technology
- Reddot Biotech

第11章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI5324

Pulmonary Surfactant Market is estimated to be valued at USD 723.2 Mn in 2026 and is expected to reach USD 947.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 723.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.20%	2033 Value Projection:	USD 947.8 Mn

Pulmonary surfactant is a complex and highly surface active material composed of lipids and proteins which is found in the fluid lining the alveolar surface of the lungs. Surfactant plays a vital role in pulmonary physiology. It's major biophysical functions is to prevent alveolar collapse at low lung volume and to preserve bronchiolar patency during normal and forced respiration, and it's major non biophysical, immunological, functions is protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms. Pulmonary surfactant is heterogeneous with respect to biochemical composition, morphological organization and specific biophysical functions. Surfactant prevents alveolar collapse at low lung volume, and preserves

bronchiolar patency during normal and forced respiration (biophysical functions). In addition, it is involved in the protection of the lungs from injuries and infections caused by inhaled particles and micro-organisms (immunological, non-biophysical functions). Pulmonary surfactant can only be harvested by lavage procedures, which may disrupt its pre-existing biophysical and biochemical micro-organization. These limitations must always be considered when interpreting ex vivo studies of pulmonary surfactant.

Market Dynamics

Increasing rate of prevalence of several respiratory infection and respiratory is expected to drive the global pulmonary surfactant market over the forecast period. For instance, on May 20, 2022, 90% of COPD (Chronic obstructive pulmonary disease) deaths were reported globally, in those under 70 years of age occur in low- and middle-income countries (LMIC) such as India, Korea and Bangladesh. Chronic obstructive pulmonary disease (COPD) is one of the major cause of death worldwide, causing 3.23 million deaths in 2019.

Increasing drug approvals for novel therapeutic agents are some of the key factors driving the global pulmonary surfactant market growth. For instance, in July 2020, Boehringer Ingelheim, a pharmaceutical company, announced that the European Commission (EC) approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF). The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020. The U.S. Food and Drug Administration (FDA), Health Canada and the Japan based pharmaceuticals and Medical Devices Agency (PMDA) approved nintedanib as the treatment for the same patient population. The approval is based on the results of INBUILD, which was a randomized, double-blind, placebo-controlled, parallel-group phase III trial, which evaluated the efficacy, safety, and tolerability of nintedanib in patients with chronic fibrosing ILDs with a progressive phenotype.

Key features of the study

This report provides an in-depth analysis of the global pulmonary surfactant market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global pulmonary surfactant market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include, Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pulmonary surfactant market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global pulmonary surfactant

Market Segmentation

By Type
- Synthetic Pulmonary Surfactant
- Animal Derived Surfactant
By Drug Type
- Poractant alfa
- Lucinactant
- Calfactant
By Indications
- Respiratory Distress Syndrome (RDS)
- Respiratory Infections
- Obstructive lung Diseases
- Others (chronic lung disease of prematurity, and surfactant protein-B deficiency)
By Route of Administration
- Intratracheal
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Boehinger Ingelheim
- AbbVie Inc
- Chiesi Farmaceutici
- ONY Biotech Inc.
- Lyomark Pharma
- Abbott
- Aviva Systems Biology Corporation
- Windtree Therapeutics, Inc
- Tekzima (Noargen)
- Biomatik
- Nanjing Norris Pharm Technology
- Reddot Biotech

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Indications
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Industry Trend
New Product Approvals/Launch
Merger and Acquisitions
PEST Analysis

4. Global Pulmonary Surfactant Market, By Type, 2026 - 2033, (USD Million)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Synthetic Pulmonary Surfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Animal Derived Surfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

5. Global Pulmonary Surfactant Market, By Drug Type, 2026 - 2033, (USD Million)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Poractant alfa
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Lucinactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Calfactant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

6. Global Pulmonary Surfactant Market, By Indications, 2026 - 2033, (USD Million)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Respiratory Distress Syndrome (RDS)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Respiratory Infections
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Obstructive lung Diseases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

7. Global Pulmonary Surfactant Market, By Route of Administration, 2026 - 2033, (USD Million)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Intratracheal
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Injectable
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

8. Global Pulmonary Surfactant Market, By Distribution Channel, 2026 - 2033, (USD Million)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

9. Global Pulmonary Surfactant Market, By Region, 2026 - 2033, (USD Million)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - UK
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Indications, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Million)
  - North Africa
  - Central Africa
  - South Africa